AM
GILD icon

Atwater Malick’s Gilead Sciences GILD Stock Holding History

Atwater Malick’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$271K Sell
1,947
-131
-6% -$18.3K 0.07% 83
2025
Q4 		$255K Buy
+2,078
New +$253K 0.07% 77
2019
Q4 		– Sell
-1,175
Closed -$74K – 101
2019
Q3 		$74K Buy
+1,175
New +$76.8K 0.06% 58

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Atwater Malick's GILD Position: Q1 2026 in Review

Atwater Malick reduced its Gilead Sciences (GILD) stake by 6.3% in Q1 2026, selling an estimated $18.3K and leaving 1,947 shares worth $271K. The position accounts for 0.07% of the portfolio, ranked #83.

Atwater Malick first reported a position in GILD in Q3 2019 and has held it in 3 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Atwater Malick held 1,947 shares of Gilead Sciences worth $271K as of Q1 2026.
  • Atwater Malick sold 131 Gilead Sciences shares in Q1 2026, an estimated $18.3K.
  • Gilead Sciences made up 0.07% of Atwater Malick's portfolio in Q1 2026, its #83 holding.
  • Atwater Malick first reported a position in Gilead Sciences in Q3 2019 and has held it in 3 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Atwater Malick's 13F filing for Q1 2026, filed 22 Apr 2026.